The Global Drug Facility was established in 2001 to address problems related to financing and regular procurement of quality-assured drugs and diagnostics for tuberculosis, and thereby help DOTS expansion.
The Global Drug Facility operates a direct procurement system to achieve competitive prices for antituberculosis drugs that meet WHO’s stringent standards, and provides in-country assistance on supply chain management.
Similarly, the Green Light Committee was established to improve access to high-quality second-line antituberculosis drugs for MDR tuberculosis at reduced prices, and to assist countries in programmatic management of MDR tuberculosis.